397030 — AprilBio Co Balance Sheet
0.000.00%
- KR₩1tn
- KR₩1tn
- KR₩2bn
Annual balance sheet for AprilBio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 54,377 | 68,784 | 63,587 | 94,482 | 92,771 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 4,459 | 436 | 925 | 1,816 | 1,837 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 59,395 | 69,359 | 66,728 | 96,626 | 94,714 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,667 | 1,337 | 1,337 | 1,200 | 1,046 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 61,376 | 71,065 | 79,702 | 99,599 | 97,120 |
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,045 | 1,787 | 21,746 | 8,482 | 542 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4,211 | 1,903 | 21,954 | 8,611 | 804 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 57,165 | 69,162 | 57,747 | 90,988 | 96,316 |
| Total Liabilities & Shareholders' Equity | 61,376 | 71,065 | 79,702 | 99,599 | 97,120 |
| Total Common Shares Outstanding |